Racura Oncology Says Potential of Proprietary Formulation to be Evaluated Early This Year; Shares Fall 7%
MT Newswires Live
Jan 29
Racura Oncology (ASX:RAC) said the potential of its proprietary formulation RC220 to prevent or slow resistance to osimertinib treatment in mutant epidermal growth factor receptor (EGFR) lung cancer will be explored in the clinic early this year, according to a Thursday filing with the Australian bourse.
Osimertinib is the current standard of care treatment for non-small cell lung cancer with defined EGFR mutations, the company said in an earlier filing.
In-patient effect of the company's lead asset and anti-cancer agent RCDS1 (E,E-bisantrene) on master cancer growth regulator MYC will be evaluated later in the year, the filing said.
Shares of the company fell past 7% in recent Thursday trade.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.